PMC9938495_01
Patient history and the periods which were evaluated in this case report. pdFVIII, plasma-derived factor VIII; ITI, immune tolerance induction; rFVIIa, recombinant activated factor VII.
gr1.jpg
PMC9938495_01_gr1.jpg
fig0001
The patient history was depicted in Figure 1.
Annualized treated-bleeding rates (ABR) and monthly direct treatment costs before (pre-emicizumab period, from Feb/27/2018 to Jul/24/2019) and during prophylaxis with emicizumab (emicizumabe period, from Jul/25/2019 to Jul/24/2020). Annualized treated-bleeding rates (bars in white; left-sided y-axis) were calculated as a proxy annual number of bleeding episodes requiring replacement treatment for hemostasis during the evaluated periods. The monthly direct treatment costs (bars in gray; right-sided y-axis) were calculated according to the prices of the respective products in United States dollar currency of the day of purchase. They were expressed by mean +- standard deviations.
gr2.jpg
PMC9938495_01_gr2.jpg
fig0002
The emicizumab price was the cost of the product purchased by the Health Secretariat of Rio Grande do Norte, according to the converted R$/mg of the last bill (Jul/06/2020) into US$/mg.a ABR and monthly treatment costs of both periods were depicted in Figure 2.